BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 30685879)

  • 1. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.
    Sparks DS; Morris B; Xu W; Fulton J; Atkinson V; Meade B; Lutton N
    Int Surg; 2015 Jan; 100(1):21-8. PubMed ID: 25594636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
    Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM
    J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
    Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
    ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
    Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
    Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
    Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
    van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
    BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.